Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea.
Center for Genome Engineering, Institute for Basic Science (IBS), 55 Expo-ro, Yuseong-gu, Daejeon 34126, Korea.
Int J Mol Sci. 2020 Oct 27;21(21):8000. doi: 10.3390/ijms21218000.
Immunotherapy is extensively investigated for almost all types of hematologic tumors, from preleukemic to relapse/refractory malignancies. Due to the emergence of technologies for target cell characterization, antibody design and manufacturing, as well as genome editing, immunotherapies including gene and cell therapies are becoming increasingly elaborate and diversified. Understanding the tumor immune microenvironment of the target disease is critical, as is reducing toxicity. Although there have been many successes and newly FDA-approved immunotherapies for hematologic malignancies, we have learned that insufficient efficacy due to disease relapse following treatment is one of the key obstacles for developing successful therapeutic regimens. Thus, combination therapies are also being explored. In this review, immunotherapies for each type of hematologic malignancy will be introduced, and novel targets that are under investigation will be described.
免疫疗法被广泛研究用于几乎所有类型的血液肿瘤，从白血病前状态到复发/难治性恶性肿瘤。由于靶细胞特征化技术、抗体设计和制造以及基因组编辑的出现，包括基因和细胞疗法在内的免疫疗法变得越来越复杂和多样化。了解目标疾病的肿瘤免疫微环境至关重要，降低毒性也是如此。尽管血液恶性肿瘤有许多成功的新的 FDA 批准的免疫疗法，但我们已经了解到，由于治疗后疾病复发导致疗效不足，是开发成功治疗方案的关键障碍之一。因此，联合疗法也在探索中。在这篇综述中，将介绍每种血液恶性肿瘤的免疫疗法，并描述正在研究的新靶点。
